Halozyme Therapeutics Inc. (NASDAQ: HALO) kicked off on Tuesday, up 0.65% from the previous trading day, before settling in for the closing price of $52.06. Over the past 52 weeks, HALO has traded in a range of $32.83-$53.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 41.16%. While this was happening, its average annual earnings per share was recorded 40.07%. With a float of $125.88 million, this company’s outstanding shares have now reached $126.77 million.
Considering the fact that the conglomerate employs 373 people, you should pay attention to its efficiency factor.
Halozyme Therapeutics Inc. (HALO) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Halozyme Therapeutics Inc. is 1.10%, while institutional ownership is 97.92%. The most recent insider transaction that took place on Jun 18 ’24, was worth 494,260. In this transaction SVP, CHIEF TECHNICAL OFFICER of this company sold 10,000 shares at a rate of $49.43, taking the stock ownership to the 168,176 shares. Before that another transaction happened on Jun 12 ’24, when Company’s Director sold 10,000 for $50.62, making the entire transaction worth $506,190. This insider now owns 99,755 shares in total.
Halozyme Therapeutics Inc. (HALO) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported 0.74 earnings per share (EPS), higher than consensus estimate (set at 0.63) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.07% per share during the next fiscal year.
Halozyme Therapeutics Inc. (NASDAQ: HALO) Trading Performance Indicators
Take a look at Halozyme Therapeutics Inc.’s (HALO) current performance indicators. Last quarter, stock had a quick ratio of 5.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.73. Likewise, its price to free cash flow for the trailing twelve months is 15.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.42, a number that is poised to hit 0.76 in the next quarter and is forecasted to reach 4.81 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc. (HALO)
Compared to the last year’s volume of 1.25 million, its volume of 1.63 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 84.59%. Additionally, its Average True Range was 1.57.
During the past 100 days, Halozyme Therapeutics Inc.’s (HALO) raw stochastic average was set at 96.98%, which indicates a significant increase from 93.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.64% in the past 14 days, which was higher than the 32.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $44.14, while its 200-day Moving Average is $39.47. Nevertheless, the first resistance level for the watch stands at $52.78 in the near term. At $53.17, the stock is likely to face the second major resistance level. The third major resistance level sits at $53.65. If the price goes on to break the first support level at $51.91, it is likely to go to the next support level at $51.43. Should the price break the second support level, the third support level stands at $51.04.
Halozyme Therapeutics Inc. (NASDAQ: HALO) Key Stats
The company with the Market Capitalisation of 6.67 billion has total of 127,274K Shares Outstanding. Its annual sales at the moment are 829,250 K in contrast with the sum of 281,590 K annual income. Company’s last quarter sales were recorded 195,880 K and last quarter income was 76,820 K.
